Heart failure (HF) remains a critical unmet medical need, affecting approximately 38 million people worldwide. Its high readmission rates, poor prognosis, and rising prevalence due to aging populations make it a significant burden, particularly in developed countries. For end-stage HF, heart transplantation is the only definitive treatment, yet fewer than 1 in 1,000 patients receive a matching heart in time. Cell therapy offers a promising alternative with the potential to revolutionize HF treatment.
OneTwenty Therapeutics is pioneering heart disease treatment using induced pluripotent stem cells (iPSCs). By reprogramming adult cells into iPSCs that can differentiate into functional heart cells, we aim to repair damaged cardiac tissue. This innovative approach targets heart failure, dilated cardiomyopathy, myocardial infarction, and other cardiovascular diseases. We have developed three platforms to tackle key challenges in this field:
